NO20083387L - mRNA spleisevariant av dobbelkortinlignende kinasegen, samt anvendelse av samme for diagnose og terapi av cancere av nevroektodermal opprinnelse - Google Patents

mRNA spleisevariant av dobbelkortinlignende kinasegen, samt anvendelse av samme for diagnose og terapi av cancere av nevroektodermal opprinnelse

Info

Publication number
NO20083387L
NO20083387L NO20083387A NO20083387A NO20083387L NO 20083387 L NO20083387 L NO 20083387L NO 20083387 A NO20083387 A NO 20083387A NO 20083387 A NO20083387 A NO 20083387A NO 20083387 L NO20083387 L NO 20083387L
Authority
NO
Norway
Prior art keywords
diagnosis
therapy
cardin
cancers
double
Prior art date
Application number
NO20083387A
Other languages
English (en)
Norwegian (no)
Inventor
Gerard Johannes Platenburg
Petra Van Kuik-Romeijn
Erno Vreugdenhil
Original Assignee
Prosensa Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosensa Bv filed Critical Prosensa Bv
Publication of NO20083387L publication Critical patent/NO20083387L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20083387A 2006-01-25 2008-07-31 mRNA spleisevariant av dobbelkortinlignende kinasegen, samt anvendelse av samme for diagnose og terapi av cancere av nevroektodermal opprinnelse NO20083387L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06075152 2006-01-25
PCT/NL2007/050025 WO2007086738A1 (en) 2006-01-25 2007-01-23 A novel mrna splice variant of the doublecortin-like kinase gene and its use in diagnosis and therapy of cancers of neuroectodermal origin

Publications (1)

Publication Number Publication Date
NO20083387L true NO20083387L (no) 2008-10-27

Family

ID=37942369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083387A NO20083387L (no) 2006-01-25 2008-07-31 mRNA spleisevariant av dobbelkortinlignende kinasegen, samt anvendelse av samme for diagnose og terapi av cancere av nevroektodermal opprinnelse

Country Status (11)

Country Link
US (1) US20110229552A1 (pt)
EP (1) EP1976989A1 (pt)
JP (1) JP2009524426A (pt)
CN (1) CN101405392A (pt)
AU (1) AU2007207987A1 (pt)
BR (1) BRPI0707272A2 (pt)
CA (1) CA2637693A1 (pt)
MX (1) MX2008009633A (pt)
NO (1) NO20083387L (pt)
WO (1) WO2007086738A1 (pt)
ZA (1) ZA200806408B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198255B2 (en) * 2008-05-16 2012-06-12 The Board Of Regents Of The University Of Oklahoma SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1
US9663585B2 (en) 2008-05-16 2017-05-30 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 monoclonal antibodies and methods of production and use thereof
CN108088990B (zh) * 2017-12-13 2020-12-22 非因生物科技(山东)有限公司 用于蛋白微阵列检测的多效性细胞蛋白提取液及制备方法
CN115154478B (zh) * 2022-06-30 2023-08-15 浙江大学医学院附属儿童医院 Zdhhc22基因在制备神经母细胞瘤治疗药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421194A1 (en) * 2001-08-22 2004-05-26 Bayer HealthCare AG Regulation of human dcamkl1-like serine/threonine protein kinase
AU2003219833A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1619251A1 (en) * 2004-07-22 2006-01-25 Prosensa B.V. A mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy

Also Published As

Publication number Publication date
WO2007086738A8 (en) 2009-07-23
US20110229552A1 (en) 2011-09-22
MX2008009633A (es) 2009-01-07
WO2007086738A1 (en) 2007-08-02
JP2009524426A (ja) 2009-07-02
EP1976989A1 (en) 2008-10-08
BRPI0707272A2 (pt) 2011-04-26
CA2637693A1 (en) 2007-08-02
ZA200806408B (en) 2009-12-30
CN101405392A (zh) 2009-04-08
AU2007207987A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
Scheepstra et al. Bivalent ligands for protein degradation in drug discovery
Grewal Why should cancer biologists care about tRNAs? tRNA synthesis, mRNA translation and the control of growth
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2115158A4 (en) DATA PROCESSING AND METHOD OF ANALYZING GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
WO2006135684A3 (en) Methods and kits for sense rna synthesis
EP2563911A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF ALANYL-TRNA SYNTHETASES
EP4375373A3 (en) Cas variants for gene editing
WO2008036691A3 (en) Biomarkers for prostate cancer and methods using the same
NO20082960L (no) Ligander med bindingsspesifisitet for VEGF og/eller EGFR og fremgangsmater for anvendelse derav
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
NO20082531L (no) Neuropilinantagonister
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2007100859A3 (en) Gene predictors of response to metastatic colorectal chemotherapy
WO2008037700A3 (en) Methods for breast cancer prognosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application